EBITDA Margin % is calculated as EBITDA divided by its Revenue. Myriad Genetics's EBITDA for the
three
months ended in Mar. 2026 was €-15.1 Mil. Myriad Genetics's Revenue for the
three
months ended in Mar. 2026 was €173.3 Mil. Therefore, Myriad Genetics's EBITDA margin for the quarter that ended in Mar. 2026 was -8.73%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Myriad Genetics EBITDA Margin % Related Terms
Myriad Genetics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs PRE, FLGT, IMDX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (STU:MYD) has a EBITDA Margin % of -8.73% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Myriad Genetics and its competitors. According to the industry distribution chart, Myriad Genetics ranks #154 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 75.5%.
Is Myriad Genetics' EBITDA Margin % too high?
Myriad Genetics' current EBITDA Margin % is -8.73%. Based on the distribution chart, Myriad Genetics ranks #154 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Myriad Genetics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' EBITDA Margin % compare to PRE and FLGT?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #154 out of 204 companies for EBITDA Margin %. This places Myriad Genetics in the lower half of its industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current EBITDA Margin % is -8.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.18, compared to a current price of €4.73 — trading 64.1% below its estimated fair value. The current EBITDA Margin % is -8.73%. Myriad Genetics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current EBITDA Margin % is -8.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €4.73 is trading 64.1% below its estimated GF Value™ of €13.18.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
EBITDA Margin %: -8.73%
GF Value™: €13.18 vs. price of €4.73 (64.1% below fair value)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score
Get the complete analysis for STU:MYD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
